SUPPLEMENTARY DATA for:

Baseline Characteristics of Canadian Patients in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)


Figure S1. Proportion of patients enrolled in PSOLAR by country and the Canadian contribution to the registry (Aug 23, 2013).
PSOLAR, Psoriasis Longitudinal Assessment and Registry.

Table S1. Baseline demographics and disease characteristics of Canadian PSOLAR patients at enrollment.

	All patients N=1896	Female N=731	Male N=1165
Race, n (%)			
White	1739 (91.7%)	682 (93.3%)	1057 (90.7%)
Black	11 (0.6)	3 (0.4%)	8 (0.7%)
Asian	73 (3.9)	21 (2.9%)	52 (4.5%)
Hispanic or Latino	7 (0.4%)	3 (0.4%)	4 (0.3%)
Other	66 (3.5%)	22 (3.0%)	44 (3.8%)
Age (y), Mean (SD)	49.0 (12.6)	49.0 (13.0)	49.0 (12.3)
Psoriasis type, n (%)			
Plaque	1881 (99.2%)	720 (98.5%)	1161 (99.7%)
Guttate	13 (0.7%)	10 (1.4%)	3 (0.3%)
Erythrodermic	3 (0.2%)	2 (0.3%)	1 (0.1%)
Pustular	18 (0.9%)	14 (1.9%)	4 (0.3%)
Inverse	4 (0.2%)	2 (0.3%)	2 (0.2%)
Duration of psoriasis (y), Mean (SD)	22.3 (12.82)	23.1 (13.94)	21.7 (12.7)
BSA by palm method (%), Mean (SD)	7.4 (11.9)	6.9 (11.4)	7.8 (12.2)
Patients with PGA data, n	**1830**	**703**	**1127**
PGA score, Mean (SD)	1.9 (1.2)	1.9 (1.1)	2.0 (1.3)
PGA score distribution, n (%)			
0 - clear	291 (15.9%)	108 (15.4%)	183 (16.2%)
1 - minimal	366 (20.0%)	147 (20.9%)	219 (19.4%)
2 - mild	532 (29.1%)	218 (31.0%)	314 (27.9%)
3 - moderate	490 (26.8%)	192 (27.3%)	298 (26.4%)
4 - marked	140 (7.7%)	37 (5.3%)	103 (9.1%)
5 - severe	11 (0.6%)	1 (0.1%)	10 (0.9%)
Patients with obesity data, n	**1881**	**724**	**1157**
BMI (kg/m^2), Mean (SD)	31.335 (6.8)	31.568 (7.6)	31.189 (6.3)
Obesity class, n (%)			
Underweight (BMI < 18.5)	5 (0.3%)	4 (0.6%)	1 (0.1%)
Normal (18.5-24.9)	282 (15.0%)	135 (18.6%)	147 (12.7%)
Overweight (25.0-29.9)	632 (33.6%)	211 (29.1%)	421 (36.4%)
Obesity class I (30.0-34.9)	488 (25.9%)	156 (21.5%)	332 (28.7%)
Obesity class II (35.0-39.9)	269 (14.3%)	118 (16.3%)	151 (13.1%)
Obesity class III (40.0 +)	205 (10.9%)	100 (13.9%)	151 (13.1%)

BMI, body mass index; BSA, body surface area; PASI, Psoriasis Area and Severity Index; PGA, Physician Global Assessment; PSOLAR, Psoriasis Longitudinal Assessment and Registry; SD, standard deviation; y, years.

Table S2. Medical and social history of Canadian PSOLAR patients at enrollment.

	All Patients N=1896	Female N=731	Male N=1165
Psoriatic arthritis, n (%)	597 (31.5%)	233 (31.9%)	364 (31.2%)
Physician confirmed	339 (17.9%)	124 (17.0%)	210 (18.0%)
Cardiovascular disease, n (%)	830 (43.8%)	313 (42.8%)	517 (44.4%)
Hypertension	656 (34.6%)	246 (33.7%)	410 (35.2%)
Hyperlipidemia	460 (24.3%)	174 (23.8%)	286 (24.5%)
Atherosclerotic disease	83 (4.4%)	20 (2.7%)	63 (5.4%)
Coronary artery disease	65 (3.4%)	14 (1.9%)	51 (4.4%)
Myocardial infarction	55 (2.9%)	8 (1.1%)	47 (4.0%)
TIA/CVA/stroke	36 (1.9%)	13 (1.8%)	23 (2.0%)
Angina	48 (2.5%)	18 (2.5%)	30 (2.6%)
Peripheral arterial disease	16 (0.8%)	7 (1.0%)	9 (0.8%)
Congestive heart failure	12 (0.6%)	3 (0.4%)	9 (0.8%)
Diabetes mellitus type II, n (%)	250 (13.2%)	91 (12.4%)	159 (13.6%)
Mental illness, n (%)	456 (24.1%)	240 (32.8%)	216 (18.5%)
Depression	329 (17.4%)	180 (24.6%)	149 (12.8%)
Anxiety	217 (11.4%)	117 (16.0%)	100 (8.6%)
Bipolar	24 (1.3%)	11 (1.5%)	13 (1.1%)
Suicidal ideation	14 (0.7%)	7 (1.0%)	7 (0.6%)
Schizophrenia	5 (0.3%)	2 (0.3%)	3 (0.3%)
Inflammatory bowel disease, n (%)	31 (1.6%)	15 (2.1%)	16 (1.4%)
Crohn's disease	13 (0.7%)	6 (0.8%)	7 (0.6%)
Indeterminate colitis	11 (0.6%)	6 (0.8%)	5 (0.4%)
Ulcerative colitis	8 (0.4%)	3 (0.4%)	5 (0.4%)
Malignancy, n (%)			
Skin cancer	61 (3.2%)	25 (3.4%)	36 (3.1%)
Melanoma	12 (0.6%)	6 (0.8%)	6 (0.5%)
Other	58 (3.1%)	33 (4.5%)	25 (2.1%)
Pulmonary, n (%)			
Sleep apnea	82 (4.3%)	28 (3.8%)	54 (4.6%)
COPD	18 (0.9%)	8 (1.1%)	10 (0.9%)
Hepatic, n (%)	49 (2.6%)	18 (2.5%)	31 (2.7%)
Alcohol use, n (%)			
Current use	1568 (82.7%)	578 (79.1%)	990 (85.0%)
Never used	184 (9.7%)	109 (14.9%)	75 (6.4%)
Have used and stopped	144 (7.6%)	44 (6.0%)	100 (8.6%)
Smoking, n (%)			
Current smoker	539 (28.4%)	219 (30.0%)	320 (27.5%)
Never smoked	598 (31.5%)	243 (33.2%)	355 (30.5%)
Prior smoker, stopped	759 (40.0%)	269 (36.8%)	490 (42.1%)

COPD, Chronic obstructive pulmonary disease; CVA, cerebrovascular accident; PSOLAR, Psoriasis Longitudinal Assessment and Registry; TIA, transient ischemic attack.

Table S3. Cardiovascular risk factors and conditions in Canadian PSOLAR patients at enrollment, by age group.

	Age Group (years)				
	12-19[a] (N=17)	20-34 (N=252)	35-44 (N=400)	45-64 (N=1036)	≥65 (N=191)
Cardiovascular, n (%)	0	21 (8.3%)	101 (25.3%)	560 (54.1%)	148 (77.5%)
Hypertension	0	16 (6.3%)	71 (17.8%)	448 (43.2%)	121 (63.4%)
Hyperlipidemia	0	8 (3.2%)	52 (13.0%)	305 (29.4%)	95 (49.7%)
Myocardial infarction	0	0	3 (0.8%)	30 (2.9%)	22 (11.5%)
Angina	0	0	1 (0.3%)	37 (3.6%)	10 (5.2%)
Atherosclerotic disease	0	0	1 (0.3%)	60 (5.8%)	22 (11.5%)
TIA/CVA/stroke	0	0	1 (0.3%)	22 (2.1%)	13 (6.8%)
Coronary artery disease	0	0	0	46 (4.4%)	19 (9.9%)
Peripheral arterial disease	0	0	0	13 (1.3%)	3 (1.6%)
Congestive heart failure	0	0	0	7 (0.7%)	5 (2.6%)
[a] PSOLAR enrolled patients aged ≥18 years					

CVA, cerebrovascular accident; PSOLAR, Psoriasis Longitudinal Assessment and Registry; TIA, transient ischemic attack.

Figure S2: Cardiovascular risk factors and conditions of Canadian PSOLAR patients at enrollment, by age group.

CVA, cerebrovascular accident; PSOLAR, Psoriasis Longitudinal Assessment and Registry; TIA, transient ischemic attack.

Table S4a. Previous non-biologic medications used by Canadian PSOLAR patients prior to enrollment.

Medication, n (%)	All patients N=1896	Female N=731	Male N=1165
Medication history data, n	**1893**	**729**	**1164**
Topical therapy	1810 (95.6%)	700 (96.0%)	1110 (95.4%)
Tazarotene	95 (5.0%)	42 (5.8%)	53 (4.6%)
Calcipotriene and bethamethasone dipropionate	85 (4.5%)	33 (4.5%)	52 (4.5%)
Light/laser therapy	1375 (72.6%)	552 (75.7%)	823 (70.7%)
Psoralen + UVA	433 (22.9%)	182 (25.0%)	251 (21.6%)
UVB	1242 (65.6%)	487 (66.8%)	755 (64.9%)
Laser	3 (0.2%)	2 (0.3%)	1 (0.1%)
Systemic corticosteroids	181 (9.6%)	80 (11.0%)	101 (8.7%)
Systemic retinoids			
Acitretin	392 (20.7%)	148 (20.3%)	244 (21.0%)
Etretinate	22 (1.2%)	6 (0.8%)	16 (1.4%)
Systemic immunomodulators	1045 (55.2%)	417 (57.2%)	628 (54.0%)
Cyclosporine	331 (17.5%)	133 (18.2%)	198 (17.0%)
Methotrexate	895 (47.3%)	363 (49.8%)	532 (45.7%)
Mycophenolate mofetil	14 (0.7%)	8 (1.1%)	6 (0.5%)
Other Immunomodulators	77 (4.1%)	22 (3.0%)	55 (4.7%)
NSAID data, n	**1895**	**731**	**1164**
Systemic NSAIDs	278 (14.7%)	108 (14.8%)	170 (14.6%)
Sulfasalazine	24 (1.3%)	9 (1.2%)	15 (1.3%)
Other NSAIDs	268 (14.1%)	103 (14.1%)	165 (14.2%)

NSAID, non-steroidal anti-inflammatory drug; PSOLAR, Psoriasis Longitudinal Assessment and Registry; UVA, ultraviolet A; UVB, ultraviolet B.

Table S4b. Previous biologic medications used by Canadian PSOLAR patients prior to enrollment.

	All patients N=1896	Female N=731	Male N=1165
Any biologic medication	1627 (85.8%)	621 (85.0%)	1006 (86.4%)
History of biologic medications at entry			
Infliximab (Remicade)	372 (19.6%)	144 (19.7%)	228 (19.6%)
Ustekinumab (Stelara)	943 (49.7%)	348 (47.6%)	595 (51.1%)
Golimumab (Simponi)	7 (0.4%)	5 (0.7%)	2 (0.2%)
Adalimumab (Humira)	429 (22.6%)	160 (21.9%)	269 (23.1%)
Alefacept (Amevive)	214 (11.3%)	72 (9.8%)	142 (12.2%)
Efalizumab (Raptiva)	221 (11.7%)	88 (12.0%)	133 (11.4%)
Etanercept (Enbrel)	541 (28.5%)	210 (28.7%)	331 (28.4%)
Other	105 (5.5%)	36 (4.9%)	69 (5.9%)
Number of biologic medications used prior to entry			
0	269 (14.2%)	110 (15.0%)	159 (13.6%)
1	843 (44.5%)	334 (45.7%)	509 (43.7%)
2	474 (25.0%)	179 (24.5%)	295 (25.3%)
3	222 (11.7%)	71 (9.7%)	151 (13.0%)
4	67 (3.5%)	28 (3.8%)	39 (3.3%)
5	19 (1.0%)	8 (1.1%)	11 (0.9%)
6	2 (0.1%)	1 (0.1%)	1 (0.1%)

PSOLAR, Psoriasis Longitudinal Assessment and Registry.

Table S5. Key clinical characteristics differentiating the Canadian and Global PSOLAR populations.

	Canadian	Global[13]
Gender, n	1896	11,900
Male, n (%)	1165 (61.4%)	6513 (54.7%)
Duration of psoriasis (y), n	1893	11777
Mean (SD)	22.3 (±12.8)	17.5 (±13.5)
PGA score at peak disease activity, n	979	6845
PGA ≥3, n (%)	926 (94.5%)	5457 (79.7%)
PGA 3 (Moderate), n (%)	552 (56.4%)	3174 (46.4%)
PGA 4 (Marked), n (%)	333 (34.0%)	1807 (26.4%)
PGA 5 (Severe), n (%)	41 (4.2%)	476 (7.0%)
Mean (SD)	3.35 (0.72)	3.1 (1.0)
BMI category, n	1881	11703
Normal (BMI 18.5-24.9), n (%)	282 (15%)	2235 (19.1%)
Overweight/obese (BMI ≥25), n (%)	1594 (84.7%)	9409 (80.4%)

BMI, body mass index; PGA, Physician Global Assessment; PSOLAR, Psoriasis Longitudinal Assessment and Registry; SD, standard deviation; y, years.